• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Iradimed withdraws 510(k) application for MR-compatible IV pump

October 12, 2022 By Sean Whooley

Iradimed logoIradimed (Nasadq:IRMD) announced that it voluntarily withdrew an FDA 510(k) application for its new model MR IV pump.

Winter Springs, Florida-based Iradimed said it learned that the FDA likely wouldn’t have time to finish clearance activities for the pending submission. Upon learning this, the company decided to voluntarily withdraw its application on Oct. 5.

The company committed to collaborating with the FDA to better understand the agency’s concerns. Iradimed said the FDA indicated its intent to provide an increased direct dialogue. This would ensure a “timelier clearance” with a replacement filing, according to a news release.

“We have been engaged in several productive and positive discussions with the FDA,” said Roger Susi, Iradimed president and CEO. “The FDA requested additional information that was not feasible to provide within the FDA’s review deadline; therefore, we decided to withdraw our application to provide us more time to understand and resolve the FDA’s concerns. We are confident that after working further with the FDA, we will be able to submit a 510(k) application that leads to a timely clearance for the MRidium 3870 Infusion Pump System.

“I also wish to point out that this withdrawn 510(k) is for a future product and in no way affects our current revenue-generating product portfolio.”

About the Iradimed MRI-compatible infusion pump system

Iradimed develops a non-magnetic intravenous (IV) infusion pump system. It designed it for safety during magnetic resonance imaging (MRI) procedures. Its MRidium MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor. It also consists of non-ferrous parts, and other unique features. It aims to deliver anesthesia safely and predictably and other IV fluids during various MRI procedures.

The company says its offering provides “a seamless approach” for safe, accurate and dependable fluid delivery. It helps critically ill patients who can’t be removed from medications before, during and after MRI scan. It also aids children and infants who must generally be sedated to remain immobile during a scan.

Preliminary third-quarter results

Iradimed also announced certain preliminary financial results for its third quarter, ended Sept. 30. It expects revenue of approximately $13.4 million. That marks a 23% rise from the same period in the previous year. It also comes in above its guidance of $13.1 million to $13.3 million.

“The third quarter preliminary results represent our highest revenue quarter and the fourth consecutive quarter of record revenues. Again, orders booked in the quarter exceeded our shipments as we continue to add to our backlog for the remainder of 2022 and into early 2023. Domestic unit orders booked in the quarter for our current MRidium 3860 Infusion Pump System were the highest over the last three years and demonstrated the continued strong demand for this product,” said Susi. “As we enter the remainder of 2022 and look forward to 2023, we believe we are positioned to continue to achieve our growth objectives with our current products.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Imaging, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Iradimed

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS